RE:RE:More dilution ?
CEO was diluted from his original position just like any other holder. He used to own more than 10% before the original financing over a year ago. He has not been able to sell unlike other shareholders. CEO has done a fine job.
The issuance price was low due to the tough times recently for biotechs. Unlucky timing but this will be forgotten soon enough. Market cap is quite low for the size of the opportunity. Welcome to biotech investing.